Insider Selling: BioLife Solutions (NASDAQ:BLFS) Insider Sells 511 Shares of Stock

Key Points

• Insider Karen Foster sold 511 shares of BioLife Solutions for a total of $13,710.13, representing a 0.26% decrease in their holdings.
• BioLife Solutions reported a loss of ($0.33) EPS for the last quarter, missing analysts' estimates, but the company had revenues of $25.42 million compared to expectations of $23.71 million.
• Equities analysts have issued various ratings on BioLife Solutions, with an average rating of "Buy" and price targets ranging up to $32.00.

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) insider Karen A. Foster sold 511 shares of BioLife Solutions stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $26.83, for a total transaction of $13,710.13. Following the sale, the insider directly owned 193,672 shares in the company, valued at approximately $5,196,219.76. The trade was a 0.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

BioLife Solutions Price Performance

Shares of BLFS stock traded down $0.71 during trading on Friday, hitting $25.57. 562,596 shares of the stock traded hands, compared to its average volume of 395,316. The firm has a market capitalization of $1.22 billion, a P/E ratio of -213.07 and a beta of 1.78. The firm's fifty day moving average price is $23.83 and its 200-day moving average price is $23.35. BioLife Solutions, Inc. has a 52-week low of $19.10 and a 52-week high of $29.55.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.31). The firm had revenue of $25.42 million for the quarter, compared to analysts' expectations of $23.71 million. BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. BioLife Solutions has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on BLFS shares. HC Wainwright reaffirmed a "buy" rating and set a $32.00 price target (up previously from $30.00) on shares of BioLife Solutions in a research report on Friday, August 8th. Zacks Research raised BioLife Solutions to a "strong-buy" rating in a research report on Monday, August 11th. Finally, Stephens initiated coverage on BioLife Solutions in a research report on Tuesday, July 22nd. They issued an "overweight" rating and a $30.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $31.29.

Hedge Funds Weigh In On BioLife Solutions

Institutional investors have recently modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of BioLife Solutions in the fourth quarter worth $31,000. State of Wyoming grew its stake in shares of BioLife Solutions by 353.1% in the first quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider's stock worth $44,000 after acquiring an additional 1,490 shares in the last quarter. US Bancorp DE grew its stake in shares of BioLife Solutions by 243.7% in the first quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider's stock worth $49,000 after acquiring an additional 1,528 shares in the last quarter. Ameritas Investment Partners Inc. grew its stake in shares of BioLife Solutions by 12.8% in the second quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider's stock worth $83,000 after acquiring an additional 441 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in shares of BioLife Solutions by 18.6% in the first quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider's stock worth $96,000 after acquiring an additional 663 shares in the last quarter. Institutional investors and hedge funds own 93.24% of the company's stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.